UPDATE 1-Impax posts Q2 below Street view
* Q2 EPS $0.48 vs est $0.51
* Q2 revenue $153.1 mln vs est $166.8 mln
Aug 3 (Reuters) - Impax Laboratories Inc (IPXL.O) posted a lower-than-expected profit, hurt by higher operating expenses.
For the second quarter, the drugmaker reported net income of $31.3 million, or 48 cents a share, compared with $3.0 million, or 5 cents a share, a year ago.
Revenue rose 162 percent to 153.1 million, helped by strong sales of generic versions of Adderall, which is used for treatment of narcolepsy and attention deficit hyperactivity disorder, and urinary drug Flomax.
Impax launched generic Flomax in March and generic Adderall in October last year.
Analysts on average expected earnings of 51 cents a share, excluding special items, on revenue of $166.8 million, according to Thomson Reuters I/B/E/S.
Total operating expenses in the quarter were up 29 percent to $34.9 million. Shares of Impax were down 1 percent at $16.50 in pre-market trade. They closed at $16.74 Monday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Prem Udayabhanu)
- Sierra Leone declares emergency as Ebola death toll hits 729 |
- S&P 500 posts worst day since April; indexes down for month
- U.S. man sues soccer star Cristiano Ronaldo over CR7 trademark
- Moscow fights back after sanctions; battle rages near Ukraine crash site |
- Netanyahu vows to complete Gaza tunnels destruction |